These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 82865)
21. [Physiopathology of renal osteodystrophy. I. Patients with kidney failure without dialysis]. Fournier A; Bordier P; Weil B; Safar M; Idatte JM Presse Med (1893); 1971 Oct; 79(45):2017-21. PubMed ID: 5119047 [No Abstract] [Full Text] [Related]
22. Effects of 25-OHD3 on renal function in pediatric patients with chronic renal failure. Mazur AT; Norman ME Miner Electrolyte Metab; 1984; 10(6):351-8. PubMed ID: 6503891 [TBL] [Abstract][Full Text] [Related]
23. [Experience in the behavior and control of renal osteodystrophy in patients under chronic hemodialysis]. Treviño Becerra A Gac Med Mex; 1975 Jun; 109(6):411-20. PubMed ID: 1149988 [No Abstract] [Full Text] [Related]
24. Improvement of early renal bone disease with alfacalcidol therapy. CMAJ; 1995 Nov; 153(10):1470, 1472. PubMed ID: 7585375 [No Abstract] [Full Text] [Related]
25. Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: an observational retrospective cohort study. De Paola L; Coppolino G; Bolignano D; Buemi M; Lombardi L Ther Apher Dial; 2010 Dec; 14(6):566-71. PubMed ID: 21118364 [TBL] [Abstract][Full Text] [Related]
26. Hypohyperparathyroidism: a model for renal osteodystrophy? Junor BJ; Edward N Postgrad Med J; 1981 Jun; 57(668):371-7. PubMed ID: 7301683 [TBL] [Abstract][Full Text] [Related]
27. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Gal-Moscovici A; Popovtzer MM Clin Nephrol; 2005 Apr; 63(4):284-9. PubMed ID: 15847255 [TBL] [Abstract][Full Text] [Related]
30. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure]. Hoshino J; Ubara Y; Takaichi K Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034 [TBL] [Abstract][Full Text] [Related]
31. [Renal osteodystrophy: role of vitamin D and parathyroid hormone]. Drüeke T; Ulmann A Nouv Presse Med; 1979 May; 8(23):1901-3. PubMed ID: 223122 [No Abstract] [Full Text] [Related]
32. PTH and bone markers of renal osteodystrophy in predialysis chronic renal failure. Coen G; Mazzaferro S; Ballanti P; Bonucci E J Endocrinol Invest; 1992; 15(9 Suppl 6):129-33. PubMed ID: 1300330 [No Abstract] [Full Text] [Related]
33. Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. Rutherford WE; Bordier P; Marie P; Hruska K; Harter H; Greenwalt A; Blondin J; Haddad J; Bricker N; Slatopolsky E J Clin Invest; 1977 Aug; 60(2):332-41. PubMed ID: 874095 [TBL] [Abstract][Full Text] [Related]
34. [Iatrogenic risk in the treatment of uremic osteodystrophy]. Giachino G; Pellerey M; Comune L; Reinero G; Francisco M Minerva Urol Nefrol; 1987; 39(2):153-6. PubMed ID: 3629413 [No Abstract] [Full Text] [Related]
35. Renal osteodystrophy: role of calcimimetics. Hörl WH Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S104-7. PubMed ID: 12612964 [TBL] [Abstract][Full Text] [Related]
36. Prevention of metabolic bone disease in the pre-end-stage renal disease setting. Coburn JW; Elangovan L J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772 [TBL] [Abstract][Full Text] [Related]